A prespecified analysis showed benefit with anselamimab in patients with kappa light chain AL amyloidosis.
|Videos|October 8, 2017
Dr. Mesa on Guideline Updates in Polycythemia Vera and Essential Thrombocythemia
Author(s)Ruben Mesa, MD
Ruben Mesa, chair of the Division of Hematology and Medical Oncology at Mayo Clinic, discusses the guideline updates in polycythemia vera and essential thrombocythemia.
Advertisement
Ruben Mesa, chair of the Division of Hematology and Medical Oncology at Mayo Clinic, discusses the guideline updates in polycythemia vera and essential thrombocythemia.
Diseases like polycythemia vera and essential thrombocythemia are unique, says Mesa, as they are malignancies, but a lot of patients have very long survival. However, some can progress.
Mesa states that the primary goal of the guidelines is the avoidance of thrombosis and bleeding in a risk-based fashion.
Advertisement
Related to this article
The selective BCR::ABL1 inhibitor ELVN-001 produced major molecular responses in previously treated chronic-phase CML, including after asciminib progression.
Actinomycin D plus low-dose cytarabine and venetoclax produced high remission rates in a retrospective cohort of patients with NPM1-mutated AML.
Revumenib added to intensive chemotherapy produced deep, MRD-negative remissions with a manageable safety profile in newly diagnosed AML.
Ofirnoflast produced hematologic improvement in two-thirds of patients with ESA-refractory lower-risk MDS.
In the phase 2 RESTORE-PV trial, DISC-3405 cut phlebotomy events and maintained hematocrit below 45% in patients with polycythemia vera.
Selcodebart improved hemoglobin levels and transfusion independence across 3 anemia cohorts in myelofibrosis, regardless of concomitant JAK inhibitor use.
The top 5 OncLive TV videos of the week cover insights in essential thrombocythemia, CML, pancreatic cancer, myelofibrosis, and chronic neutropenia.
Advertisement
Advertisement
Trending on OncLive
1
Ofirnoflast Elicits Durable Transfusion Independence, Hematologic Improvement in Lower-Risk MDS
2
ACTIVE Regimen Elicits High Response Rates in R/R NPM1-Mutated AML
3
Revumenib Plus Chemo Yields High Response and MRD-Negativity Rates in Newly Diagnosed NPM1+ or KMT2A+ AML
4
Dr Gangat on Phase 2 Efficacy and Safety Data for DISC-3405 in Polycythemia Vera
5